AusperBio to Unveil Groundbreaking Clinical Data Updates at EASL Congress 2024
AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. are set to present groundbreaking clinical data updates on their molecule AHB-137 at the EASL™ Congress 2024. The Phase I trials focus on achieving a functional cure for chronic hepatitis B, a prevalent liver disease affecting millions globally. Learn more about the innovative research efforts at the official EASL™ Congress website.
Namibia Achieves Milestone in Ending Mother-to-Child Transmission of HIV and Hepatitis B
Namibia achieves milestone in fighting mother-to-child transmission of HIV and hepatitis B, becoming first in Africa to do so. With almost universal HIV testing among pregnant women and a 70% reduction in vertical transmission, only 4% of babies born to HIV-positive mothers acquired the virus in 2022. WHO awards Namibia for progress in reducing hepatitis B and combating HIV, highlighting the country’s strategic approach to disease elimination.